Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yi Qi Yang Yin Decoction (YQYY) is a traditional Chinese medicine (TCM) herbal formula, not a conventional single-molecule pharmaceutical. As a complex botanical mixture, its formulation can vary, but specific compositions have been described for clinical use. For instance, one version consists of nine herbs, including Radix Astragali and Radix Ginseng, while another variant, Yiqi Yangyin Jiedu Decoction (YYJD), includes herbs like milkvetch root and spikemoss herb. Based on the TCM theory of treating Qi and Yin deficiency, YQYY is believed to act through multiple biological targets and pathways. It has been investigated in numerous clinical trials in China for various conditions, including non-small cell lung cancer, breast cancer, diabetic retinopathy, and type 2 diabetes with nonalcoholic fatty liver disease (NAFLD). In cancer, it is often used in combination with chemotherapy or targeted therapies like osimertinib to improve quality of life, enhance immune function, and potentially delay drug resistance. Mechanistic studies suggest it may affect signaling pathways such as EGFR-PI3K-AKT and inflammation-related pathways like NF-κB.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yi Qi Yang Yin Decoction.